Please provide your email address to receive an email when new articles are posted on . For the open-label COVID-19 Cardiolink-9 study, the researchers randomly assigned 100 symptomatic patients with ...
Patients in the placebo arm of REDUCE-IT, who received mineral oil, saw worsening levels of numerous biomarkers linked to atherosclerotic disease during the trial, while those in the icosapent ethyl ...
Much like in the overall REDUCE-IT trial, icosapent ethyl (Vascepa; Amarin) reduced a broad range of adverse clinical outcomes in the large subgroup of patients who had undergone a prior PCI, a ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The mechanism ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results